APA

Agarwal N., Bellmunt J., Maughan B. L., Boucher K. M., Choueiri T. K., Qu A. Q., Vogelzang N. J., Fougeray R., Niegisch G., Albers P., Wong Y., Ko Y., Sridhar S. S., Tantravahi S. K., Galsky M. D., Petrylak D. P., Vaishampayan U. N., Mehta A. N., Beer T. M., Sternberg C. N., Rosenberg J. E. & Sonpavde G. (20141105). Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. : Clinical genitourinary cancer.

Chicago

Agarwal Neeraj, Bellmunt Joaquim, Maughan Benjamin L, Boucher Kenneth M, Choueiri Toni K, Qu Angela Q, Vogelzang Nicholas J, Fougeray Ronan, Niegisch Guenter, Albers Peter, Wong Yu-Ning, Ko Yoo-Joung, Sridhar Srikala S, Tantravahi Srinivas K, Galsky Matthew D, Petrylak Daniel P, Vaishampayan Ulka N, Mehta Amitkumar N, Beer Tomasz M, Sternberg Cora N, Rosenberg Jonathan E and Sonpavde Guru. 20141105. Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. : Clinical genitourinary cancer.

Harvard

Agarwal N., Bellmunt J., Maughan B. L., Boucher K. M., Choueiri T. K., Qu A. Q., Vogelzang N. J., Fougeray R., Niegisch G., Albers P., Wong Y., Ko Y., Sridhar S. S., Tantravahi S. K., Galsky M. D., Petrylak D. P., Vaishampayan U. N., Mehta A. N., Beer T. M., Sternberg C. N., Rosenberg J. E. and Sonpavde G. (20141105). Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. : Clinical genitourinary cancer.

MLA

Agarwal Neeraj, Bellmunt Joaquim, Maughan Benjamin L, Boucher Kenneth M, Choueiri Toni K, Qu Angela Q, Vogelzang Nicholas J, Fougeray Ronan, Niegisch Guenter, Albers Peter, Wong Yu-Ning, Ko Yoo-Joung, Sridhar Srikala S, Tantravahi Srinivas K, Galsky Matthew D, Petrylak Daniel P, Vaishampayan Ulka N, Mehta Amitkumar N, Beer Tomasz M, Sternberg Cora N, Rosenberg Jonathan E and Sonpavde Guru. Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. : Clinical genitourinary cancer. 20141105.